Ann: Inhibition of SARS-CoV-2 by MPL in Human Respiratory Cells, page-130

I think you Pee spot on about PAA might be moving away from WEHI
IMO PAA got same level of frustration with SH. Things moving at WEHI are too slow and WEHI is not pursue the same solution what MPL will provide.Dr Tham interview yesterday is pre-caustious antibiotic (just like another pineapple spray in different usage) .but not treatment like we initially expected. And also this antibiotic will not available until next year. that is 4 months to go and here we are winging about 2 months... so that not robust.

Take a look at this paragraph, it was put there to tell us there expression without clarification. but i think
"This work requires repetition and robust verification" .... plainly speaking PAA said it take 2 months to get this far?
No that is not robust enough.


Now We confirming that MPL having same effect with human organ cell - human lung Calu-3. which need to be repeatedly test and and confirm on other organs like kidney etc... in which WEHI cannot provided. As it clearly said it WEHI cannot provide test environment where patients with condition disease. so we dont want to waste anytime here and discuss with other group.



This is why i said in other thread... this announce seem to be left open for another announcement.
May partners with someone else and depend on how big they are comparing to WEHI but as mention they will be more experience
dealing with what they after... I just had feeling it is some hospitals.

All my opinion so do your own research.